Partial correction of the dwarf phenotype by non-viral transfer of the growth hormone gene in mice: Treatment age is critical

Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society
Eliza HigutiCibele Nunes Peroni

Abstract

Non-viral transfer of the growth hormone gene to different muscles of immunodeficient dwarf (lit/scid) mice is under study with the objective of improving phenotypic correction via this particular gene therapy approach. Plasmid DNA was administered into the exposed quadriceps or non-exposed tibialis cranialis muscle of lit/scid mice followed by electroporation, monitoring several growth parameters. In a 6-month bioassay, 50μg DNA were injected three times into the quadriceps muscle of 80-day old mice. A 50% weight increase, with a catch-up growth of 21%, together with a 16% increase for nose-to-tail and tail lengths (catch-up=19-21%) and a 24-28% increase for femur length (catch-up=53-60%), were obtained. mIGF1 serum levels were ~7-fold higher than the basal levels for untreated mice, but still ~2-fold lower than in non-dwarf scid mice. Since treatment age was found to be particularly important in a second bioassay utilizing 40-day old mice, these pubertal mice were compared in a third bioassay with adult (80-day old) mice, all treated twice with 50μg DNA injected into each tibialis cranialis muscle, via a less invasive approach. mIGF1 concentrations at the same level as co-aged scid mice were obtained 15days after administrati...Continue Reading

References

Sep 1, 1997·Human Molecular Genetics·I DankoJ A Wolff
Mar 7, 2003·Gene Therapy·H GollinsD J Wells
Mar 27, 2003·American Journal of Physiology. Endocrinology and Metabolism·Morten SondergaardThomas G Jensen
Oct 4, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Maria Helena BelliniPaolo Bartolini
May 27, 2004·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Jillian M McMahon, Dominic J Wells
Oct 30, 2004·The Journal of Gene Medicine·Elena FattoriNicola La Monica
May 11, 2006·The Journal of Gene Medicine·Amiq GazdharRalph Alexander Schmid
Mar 30, 2007·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Mogher KhamaisiAllan Flyvbjerg
Mar 12, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mark WallaceLuwy Musey
Oct 8, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Amir S KhanMarta L Fiorotto
Oct 6, 2011·Endocrinology·Maximilian BielohubyMartin Bidlingmaier
Oct 26, 2011·Current Gene Therapy·Tatsufumi Murakami, Yoshihide Sunada
Aug 21, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Hirofumi MakinoRyuichi Morishita
Jan 29, 2013·The Journal of Gene Medicine·Samantha L GinnJo Wixon
Feb 27, 2013·Current Pharmaceutical Biotechnology·Weiwei WangGustav Steinhoff
Jan 24, 2014·Endocrine Reviews·Kyriaki S AlatzoglouMehul T Dattani

❮ Previous
Next ❯

Citations

Nov 5, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Eliana Rosa LimaCibele Nunes Peroni

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.